DiaCarta
Hayward
About DiaCarta
DiaCarta provides precise cancer molecular tests including NRAS, EGFR and KRAS mutation test kits, PCR ready lysis kit, HPV E6/E7 mRNA test kits for cervical and head-neck cancer, cancer biomarker gene expression detection kits and superfast master mix. DiaCarta supplies precise molecular diagnostic cancer assays that enable the most sensitive, reliable, and accurate detection of cancer biomarkers directly from a patient sample, including QClamp gene mutation tests, SuperbDNA gene expression assays, and QZol, the only PCR ready lysate solution . DiaCarta's NRAS, EGFR, and KRAS tests are highly sensitive and able to detect a broad set of mutations and are being used by hospitals and cancer clinical laboratories for the treatment of patients and by biotechnology and pharmaceutical companies for clinical research.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $98.2M
- Funding stage: Early Stage Venture
- Last round: Series B (Feb 2018)
- Website: diacarta.com
- Phone: (510) 314-8858
Industries & Categories
Biotechnology, Genetics, Medical
Social Profiles
Canonical: https://fsome.com/organization/diacarta-88303 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.